Castration-resistant prostate cancer: Where are we going?;Cáncer de próstata resistente a castración: ¿Hacia dónde vamos?

Actas Urologicas Espanolas

Volumn 36, Issue 6, 2012, Pages 367-374

  Alcaraz, A ^a   Medina, R ^b   Maroto, P ^c   Climent, M A ^d   Castellano, D ^e   Carles, J ^f  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f Instituto de Oncología de la Vall d'Hebron   (Spain)

Author keywords

Cabazitaxel; Castration resistant prostate cancer; Hormonal therapies; Metastatic prostate cancer; Progression

Indexed keywords

EID: 84861597678     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2011.10.010     Document Type: Short Survey

References (44)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. M.R. Cooperberg, J.W. Moul, and P.R. Carroll The changing face of prostate cancer J Clin Oncol 23 2005 8146 8151
3. E.M. Uchio, M. Aslan, C.K. Wells, J. Calderone, and J. Concato Impact of biochemical recurrence in prostate cancer among US veterans Arch Intern Med 170 2010 1390 1395
4. M.A. Eisenberger, R. Simon, P.J. O'Dwyer, and H.A. Friedman A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma J Clin Oncol 3 1985 827 841
5. A. Yagoda, and D. Petrylak Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer Cancer 71 1993 1098 1109
6. I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi On behalf of the TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
7. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara, J.A. Jones, and M.E. Taplin Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
8. D.L. Berry, C.M. Moinpour, C.S. Jiang, D.P. Ankerst, D.P. Petrylak, and L.V. Vinson Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone J Clin Oncol 24 2006 2828 2835
9. I.F. Tannock, D. Osoba, M.R. Stockler, D.S. Ernst, A.J. Neville, and M.J. Moore Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
10. E.M. Van Allen, and C.J. Ryan Novel secondary hormonal therapy in advanced prostate cancer: an update Curr Opin Urol 19 2009 315 321
11. E.J. Small, S. Halabi, N.A. Dawson, W.M. Stadler, B.I. Rini, and J. Picus Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALBG 9583) J Clin Oncol 22 2004 1025 1033
12. A.O. Sartor, C.M. Tangen, M.H. Hussain, M.A. Eisenberger, M. Parab, and J.A. Fontana Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426) Cancer 112 2008 2393 2400
13. R. Joyce, M.A. Fenton, P. Rode, M. Constantine, L. Gaynes, and G. Kolvenbag High dose bicalutamide for androgen-independent prostate cancer: effect of prior hormonal therapy J Urol 159 1998 149 153
14. M. Scholtz, R. Jennrich, S. Strum, S. Brosman, H. Johnson, and R. Lam Long-term outcome with androgen independent prostate cancer treated with ketoconazole and hidrocortisone J Urol 173 2005 1947 1952
15. O. Sartor, M. Weinberger, A. Moore, A. Li, and W.D. Figg Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer Urology 52 1998 252 256
16. W.K. Oh, P.W. Kanthoff, V. Weinberg, G. Jones, B.I. Rini, and M.K. Derynck Prospective, multicentre, randomized phase II trial of the herbal supplement PC-SPES and diethylbestrol in patients with androgen-independent prostate cancer Clin Oncol 22 2004 3705 3712
17. M. Orlando, A. Chacon, G. Salum, and D.R. Chacon Low dose continuous oral fosfestrol is highly active in hormone refractory prostate cancer Ann Oncol 11 2000 177 181
18. S.J. Hotte, and F. Saad Current management of castrate-resistant prostate cancer Curr Oncol 17 Suppl 2 2001 S72 S79
19. S.D. Fossa, E. Paus, M. Lindegaard, and D.W. Newling Prostate specific-antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment Br J Urol 69 1992 175 179
20. S. Akimoto, M. Masai, K. Akakura, and J. Shimazaki Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time Eur Urol 27 1995 207 212
21. M. Hussain, B. Goldman, C. Tangen, C.S. Higano, D.P. Petrylak, and G. Wilding Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 J Clin Oncol 27 2009 2450 2456
22. S. Halabi, N.J. Vogelzang, S.S. Ou, K. Owzar, L. Archer, and E.J. Small Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer J Clin Oncol 27 2009 2766 2771
23. T. Nelius, and S. Filleur PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy Prostate 69 2009 1802 1807
24. D.C. Danila, G. Heller, G.A. Gignac, R. Gonzalez-Espinoza, A. Anand, and E. Tanaka Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin Cancer Res 13 2007 7053 7058
25. S. Halabi, E.J. Small, P.W. Kantoff, M.W. Kattan, E.B. Kaplan, and N.A. Dawson Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237
26. P.W. Kantoff, S. Halabi, M. Conaway, J. Picus, J. Kirshner, and V. Hars Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study J Clin Oncol 17 1999 2506 2513
27. Park SC, Lee JW, Rim JS. Docetaxel-based Systemic Chemotherapy in Elderly Korean Men with Castration-resistant Prostate Cancer. Actas Urol Esp. 2012. En prensa.
28. H.I. Scher, S. Halabi, I. Tannock, M. Morris, C.N. Sternberg, M.A. Carducci Prostate Cancer Clinical Trials Working Group Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
29. H.I. Scher, M. Warren, and G. Heller The association between measures of progression and survival in castrate metastatic prostate cancer Clin Cancer Res 13 2007 1488 1492
30. A.J. Armstrong, E. Garret-Mayer, R. de Wit, I. Tannock, and M. Eisenberger Prediction of survival following first line chemotherapy in men with castration resistant metastatic prostate cancer Clin Cancer Res 16 2010 203 211
31. D.R. Berthold, G.R. Pond, R. de Wit, M. Eisenberger, and I.F. Tannock Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann Oncol 19 2008 1749 1753
32. A. Fontana, L. Galli, A. Fioravanti, P. Orlandi, C. Galli, and L. Landi Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and dexamethasone in advanced hormone-refractory prostate cancer Clin Cancer Res 15 2009 4954 4962
33. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin demonstrates a significant clinical benefit in patients with HRPC: Results of a randomized phase III trial. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007;25:5019.
34. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, and L. Chu Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
35. H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, and E. Efstathiou Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
36. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, and D.F. Penson (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
37. K.N. Chi, S.J. Hotte, E.Y. Yu, D. Tu, B.J. Eigl, and I. Tannock Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 4247 4254
38. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein, L.M. Glode, D.L. Bilhartz, and M. Wyand Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
39. G. Attard, A. Greystoke, S. Kaye, and J. de Bono Update on tubulin binding agents Pathol Biol (Paris) 54 2006 72 84
40. J.S. de Bono, S. Oudard, M. Ozguroglu, S. Hansen, J.P. Machiels, and I. Kocak Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial Lancet 376 2010 1147 1154
41. J.M. Cózar-Olmo, J. Carballido Rodriguez, P. Luque Gálvez, A.G. Tabernero Gómez, A. Barreiro Mouro, and E. Sánchez Sánchez Efectividad y tolerabilidad del ácido zoledrónico en el tratamiento del cáncer de próstata metastásico Actas Urol Esp 32 2008 492 501
42. K. Fizazi, M. Carducci, M. Smith, R. Damião, J. Brown, and L. Karsh Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
43. N. Mottet, J. Bellmunt, M. Bolla, S. Joniau, M. Mason, and V. Matveev Guía de la EAU sobre cáncer de próstata. Parte II: tratamiento del cáncer avanzado, recidivante y resistente a la castración Actas Urol Esp 35 2011 565 579
44. G. Sonpavde, and C.N. Sternberg Contemporary management of metastatic castration-resistant prostate cancer Curr Opin Urol 21 2011 241 247